Pizensy

(Lactitol)

Phase 2Small molecule

BBraintree Laboratories

Pizensy is one of 25 small molecule programs targeting Pneumonia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

PneumoniaPhase 2

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Prevacid

Takeda

Preclinical

1 2

Pizensy

BBraintree Laboratories

Phase 2

1 3

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

12 4

Zantac 150

CChattem

Preclinical

2 5

Alka-Seltzer

AAbbott

Preclinical

1 6

Pepcid

KKenvue Brands

Preclinical

1 7

Aciphex

Akero Therapeutics

Preclinical

1 8

Mucinex

AAultman Health Foundation

Preclinical

1 9

Tagamet

DDT MedTech, LLC

Preclinical

1 10

Protonix

WWyeth-Lederle Vaccines

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pneumonia1 trial

Pilot Study of the Effectiveness of Probiotics and Lactitol for the Decolonization of OXA-48 (Carbapenemase) Producing Klebsiella Pneumoniae Among Rectal Carriers

Unknown status·IInstituto de Investigación Hospital Universitario La Paz·Phase 2·NCT02307383·20 enrolled

Regulatory

FDA Approval Timeline[4]

Feb 12, 2020

PIZENSY

NDA NDA211281

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lactitol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lactitol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lactitol. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA211281). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Pizensy. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Braintree Laboratories company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBraintree Laboratories

Patent Landscape[5]

Patent Cliff

May 12, 2037

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10806743May 12, 2037

Pizensy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pneumonia1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News